that Pfizer has once again pushed
ahead of Novartis and Roche for
the Worldwide Prescription Drug
Sales number one spot in 2024.
Novartis is also due to jump up to
the number two spot after exhibiting 2.3% CAGR between 2018-24
as opposed to Roche’s 0.8% CAGR.
Bristol-Myers Squibb has fallen
out of the top 10 largely due to
loss of Opdivo market-share to
Keytruda and being beaten to the
mega-merger table by Takeda with
Both of these products are still
forecast to retain spots within the
world’s top 10 selling drugs in
2024. (Figure 1)
Drug Sales in 2024: Top
Pfizer returns to top spot for
worldwide sales of prescription-drugs in 2024.
As the top three continue to battle
it out, EvaluatePharma® finds
its acquisition of Shire in January
2019. As a result, Takeda leaps
up seven places in the ranking
between 2018 and 2024 with an
impressive 10.8% CAGR.
Bristol-Myers Squibb is unlikely to
be outside the top 10 for too long,
however, as on January 3rd, 2019,
the company announced a $74B
acquisition of Celgene that it is yet
Figure 1: Worldwide Prescription Drug Sales (2010-2024)
Figure 2: Worldwide Prescription Drug Sales in 2024